Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK3739937 in Healthy Participants
NCT04493684Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3739937 in human immunodeficiency virus infection (HIV) (15 arms), sponsored by ViiV Healthcare. Primary endpoints: Number of Any Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 16 weeks, Change From Baseline in Hematology Parameters at Day 15 and 7 more. Started Jul 2020; status: completed.
02
Drugs
GSK3739937
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04493684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493684.